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Editorial Comment
Effects of Serotonin and
Thromboxane A2 on the
Coronary Collateral Circulation*
L. MAXIMILIAN BUJA, MD, FACC,
JAMES T. WILLERSON, MD, FACC
Houston, Texas
Role of platelets and platelet products in ischemic heart
disease. Platelet aggregation and activation are important
factors in the pathogenesis of acute ischemic heart disease in
many patients, and their role has been confirmed in human
and animal studies (1-4). At a certain stage of evolution of
coronary atherosclerosis, the endothelium on the surface of
plaques becomes sufficiently injured or dysfunctional to
initiate platelet aggregation and activation. Products re-
leased from the platelets and injured endothelium are ex-
tremely important in mediating further platelet aggregation
and secondary effects on the vasculature. The platelet-
derived mediators include adenosine diphosphate, throm-
boxane A2 and serotonin, whereas the endothelium may
release platelet-activating factor and endothelin (4-6). Acute
ischemic heart disease may be precipitated by platelet-
mediated processes, which include worsening of coronary
stenosis due to platelet deposition on a plaque (1-4); acute
coronary narrowing mediated by thromboxane A2 and sero-
tonin released from activated platelets and the accumulation
of thrombin (7,8); microvascular narrowing in the coronary
circulation due to platelet embolization; generalized activa-
tion of platelets with release of chemical mediators; and
activation of the coagulation system with subsequent occlu-
sive thrombosis at the unstable coronary lesion (1-4).
The importance of platelet-mediated processes is high-
lighted by current emphasis on the development and testing
of pharmacologic agents to inhibit platelet aggregation and
platelet-derived chemical mediators (4-6). In addition to the
immediate effects, platelet activation may contribute to the
long-term problems of atherogenesis and recurrent stenosis
as a result of the stimulation of smooth muscle proliferation
secondary to release of the platelet-derived growth factor
and other growth factors (4).
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The Present Study
Main findings and conclusions. The study by Wright et al.
(9) in this issue of the Journal addresses the consequences of
platelet activation and release of platelet-derived hormones
on the coronary collateral circulation in a canine model with
collateral development induced by gradual occlusion of the
mid-left anterior descending coronary artery. The data were
carefully obtained under well controlled conditions. Seroto-
nin and U46619, a stable analogue of thromboxane A2, were
separately injected into the left main coronary artery. Wright
and colleagues (9) found that serotonin (50 JLg/min) and
U46619 (0.01 JLg/kg per min) caused significant decreases in
retrograde blood flow (48 ± II%and 38 ± 13%, respectively)
and total collateral flow (36 ± 10% and 34 ± 13%, respec-
tively). Serotonin caused a significant increase in total tissue
flow to the subepicardium of the collateral-dependent region,
whereas U46619 caused no change in tissue blood flow. The
authors (9) conclude that both serotonin and thromboxane
A2 can cause vasoconstriction of interarterial coronary col-
lateral vessels, and they suggest that platelet activation in
coronary arteries that are linked to collateral vessels has the
potential to cause collateral vasoconstriction, thereby com-
promising blood flow to the dependent myocardium.
Potential clinical significance. The potential clinical rele-
vance of these findings (9) is related to the significant
myocardial dependence on collateral perfusion in many
patients with ischemic heart disease and the consequent risk
for ischemic injury if the coronary collateral circulation is
impaired. The present study (9) clearly suggests that platelet-
derived vasoactive agents can adversely affect this circula-
tion. Nevertheless, several issues should be evaluated in
assessing the significance of the study results,
Perspectives. Basic aspects of the model should be con-
sidered. First, because the experiments were performed in
anesthetized open chest dogs, the results may differ from
those that might be expected in awake subjects. However, as
Wright et al. (9) point out, general anesthesia and surgery
cause neuroendocrine activation that increases the basal
level of vasoconstriction in the coronary system. The pres-
ence of increased coronary vasoconstrictor tone would
lessen the degree of further coronary constriction in re-
sponse to the agents tested. Therefore, the responses ob-
served may underestimate those that would occur in an
intact awake animal preparation. Second, most collateral
vessels in the canine heart are located in the epicardium. As
a result, most of the coronary collateral flow, and most of the
change in collateral flow in response to both serotonin and
U46619, was accounted for by retrograde blood flow. How-
ever, in humans with coronary artery disease, the intramural
collateral vessels are probably more significant than they are
in the dog. This difference leaves an open question: How
similar are the responses to the vasoactive agents of humans
with coronary artery disease and the dog model?
How relevant are the doses of serotonin and thrombox-
ane used to the levels that may occur naturally in pathophys-
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iologic states? Wright et al. (9) were able to calculate the
total blood flow to the left main coronary artery into which
the vasoactive agents were diluted. As assessed by these
measurements, infusion of serotonin at a dose of 10 JLg/min
resulted in a computed coronary artery blood concentration
of approximately 6 x 10-6 M. The authors cite evidence that
this level is within the range previously reported to occur
during coronary artery thrombus formation in a canine
model, and less than serotonin concentrations achieved by
aggregating platelets in numbers found in circulating blood
(7). They also point out that, although coronary artery blood
concentrations of thromboxane Az during thrombotic arte-
rial occlusion have not been published, the concentration of
U46619 achieved in their study was less than that which has
been reported to produce maximal coronary artery vasocon·
striction in vitro. Thus, the drug concentrations observed
appear to be within the range that could be expected to occur
during platelet aggregation in vivo.
The differential effect of serotonin and thromboxane on
total myocardial blood flow, with serotonin providing an
increase and thromboxane no change, is an interesting
additional finding. The increase in myocardial blood flow in
response to serotonin is an indication of the vasodilator
effect of serotonin on the coronary resistance vessels. Could
the increase in myocardial blood flow in response to seroto-
nin be mediated by release of endothelium-derived relaxing
factor? This observation requires further investigation.
Implications. The significance of the findings of Wright et
al. (9) could be strengthened by using specific serotonin and
thromboxane Azantagonists and demonstrating blockade of
the effects of serotonin and thromboxane Az on coronary
collateral vessels (4-6). Such studies to characterize the
receptor activity of the coronary collateral vessels are
judged to be important and necessary. Nevertheless, the
present study makes the provocative observation that the
effects ofplatelet aggregation are not limited to local changes
at the site of a coronary stenosis but are probably more
generalized in the coronary circulation, where they have the
potential to produce significant impairment of the coronary
collateral circulation.
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